Aligos Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aligos Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-12-31 was $0.00.
- Aligos Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Aligos Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Aligos Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-03-31 was $23.00K, a 130.00% increase year-over-year.
- Aligos Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $23.00K, a 15.00% increase from fiscal 2022.
- Aligos Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $20.00K, a 94.92% decline from fiscal 2021.
- Aligos Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $394.00K, a 50.96% increase from fiscal 2020.
- Aligos Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $261.00K, a 43.38% decline from fiscal 2019.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $23.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $23.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $32.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $23.00K 10-Q · filed 2024-05-07 | $33.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $20.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | $9.00K 10-Q · filed 2023-11-02 | $87.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $1.00K 10-Q · filed 2023-08-03 | $96.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $10.00K 10-Q · filed 2023-05-04 | $308.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $394.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $18.00K 10-Q · filed 2022-11-02 | $345.00K derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $213.00K 10-Q · filed 2022-08-04 | $475.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $96.00K 10-Q · filed 2022-05-04 | $338.00K derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $261.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | $148.00K 10-Q · filed 2021-11-04 | $633.00K derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $76.00K 10-Q · filed 2021-08-05 | $555.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $18.00K 10-Q · filed 2021-05-10 | |
| 2019-12-31 | $391.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $461.00K 10-K · filed 2021-03-23 |
| 2019-09-30 | $70.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |